MediPharm Labs Corp.
MEDIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $12 | $11 | $12 |
| % Growth | -3% | 9.3% | -10.3% | – |
| Cost of Goods Sold | $9 | $8 | $7 | $8 |
| Gross Profit | $3 | $3 | $4 | $4 |
| % Margin | 22.4% | 28.2% | 38.7% | 30% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $6 | $3 | $6 |
| SG&A Expenses | $5 | $7 | $5 | $5 |
| Sales & Mktg Exp. | $1 | $1 | $1 | -$1 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $5 | $7 | $5 | $5 |
| Operating Income | -$2 | -$4 | -$0 | -$2 |
| % Margin | -19.1% | -32.2% | -4.1% | -15% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$4 | -$0 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$4 | -$0 | -$2 |
| % Margin | -18.7% | -31.9% | -3.6% | -14.3% |
| EPS | -0.01 | -0.009 | -0.001 | -0.004 |
| % Growth | -9.9% | -911.1% | 78.6% | – |
| EPS Diluted | -0.01 | -0.009 | -0.001 | -0.004 |
| Weighted Avg Shares Out | 421 | 415 | 415 | 415 |
| Weighted Avg Shares Out Dil | 421 | 415 | 415 | 415 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$2 | -$3 | $0 | -$1 |
| % Margin | -14.9% | -28.3% | 0.5% | -9.5% |